Dec 15 (Reuters) - UK's health regulator on Monday approved GSK's twice-yearly drug for use as an add-on treatment for asthma ...

The MHRA has approved depemokimab as an add on treatment for severe asthma and chronic rhinosinusitis with nasal polyps.

The updated asthma diagnosis pathway places stronger emphasis on FeNO testing and structured clinical assessment.

GSK plc announced the marketing authorisation of Exdensur (depemokimab) by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). In the UK, Exdensur is now approved in two indications: ...

Advice on recommended inhaler treatment regimens for asthma, and the shift to SABA-free care, and how to embed these regimens in practice ...

As with any medicine, the MHRA will keep the safety and effectiveness of depemokimab under close review. The Medicines and Healthcare products ...

A new way to treat asthma symptoms and even repair previously irreversible lung damage could be on the horizon following the discovery of a potential new therapeutic target by scientists at the ...

Monthly monoclonal antibody injection tezepelumab is so effective in patients with severe asthma, half are able to stop daily ...

If you fall into any sort of 'underlying health conditions' bracket, you're likely extra concerned about the novel coronavirus pandemic. And if you deal with asthma – caused by the inflammation of the ...

They found that an injected antibody called tezepelumab allowed 90% of people with severe asthma to reduce their use of daily ...